• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    WuXi STA Opens High-Potency API Plant

    Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility

    Phastar Appoints Chris Schoonmaker as Chief Operations Officer
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    WuXi STA Opens High-Potency API Plant

    Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility

    Shimadzu Scientific Instruments Extends HQ Campus
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Takeda to Expand U.S. Footprint

    Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Biosynth Carbosynth

    Aphena Pharma Solutions

    Qosina

    Vector Partners Limited
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Biosynth Carbosynth

    Aphena Pharma Solutions

    Qosina

    Vector Partners Limited
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Sustainability: A New Threat or Opportunity for CDMOs?

    CDMOs must be proactive in adapting to the sustainability standards of pharma companies.

    Sustainability: A New Threat or Opportunity for CDMOs?
    Sustainability: A New Threat or Opportunity for CDMOs?
    Figure 1. The three GHG emission “Scopes” (Source: adapted from literature)
    Sustainability: A New Threat or Opportunity for CDMOs?
    Figure 2. E Factor in API synthesis dwarf those observed in the petrochemical industry (Source: adapted from literature)
    Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers05.02.22
    For a few years now sustainability has become one of the most widely heard, read, used and abused words not only in political, business and financial cenacles but also among the general public.

    In its broadest possible sense, the term sustainability refers to the ability of a system to maintain or sustain itself over time.1

    The sustainability concept is not new. Its roots can be traced back more than three hundred years ago when it was associated with forest and other agricultural management practices aiming to maintain soil fertility.2 Sustainability has won its spurs and acquired new dimensions thanks to “Our Common Future” report—also referred to as the Brundtland report—issued in 1987 by the United Nations World Commission and the Environment and Development.3

    Our Common Future introduces the idea of sustainable development—defined as “meeting the needs of the present without compromising the ability of future generations to meet their own needs.” It recognizes and stresses that sustainability revolves around three irrefragably interlinked and interdependent pillars: the environment, society and the economy.

    Society as a whole, including most industries and companies around the world, are increasingly embracing and adopting sustainable business practices and integrating ecological concerns with societal and economic considerations. These days, sustainability is becoming a cornerstone of corporate strategies. The metrics applied by organizations for measuring their performance more and more go beyond just financial indicators by taking into account societal and environmental quantitative scores—embracing what is often referred to as “triple bottom line” performance metrics seeking to achieve an optimal balance between “Profit, People and Planet.”4

    The attention given to sustainability seeks to ensure alignment between socio-political developments and the concern and objectives of its various stakeholders. This includes not only the general public and customers but also financial investors—recent surveys indicate that sustainability is considered by more than 50% of these as a fundamental element in their investment decisions.5 It also aims to ensure that companies are effectively positioned for grabbing the new opportunities expected to be created by the drive towards sustainability—examples include savings associated with waste reduction or the introduction of new products or technologies.

    This drive towards sustainability has received a new impulse by the pledge of various countries, including the European Union and the United States to reduce by 2030 their greenhouse gases (GHG) emissions by 55% compared to their 1990 levels and become carbon neutral by 2050 in order to meet the objectives set in the Paris Climate Accord. The Accord was signed in 2015 by 196 countries and aims to “lower global warming well below 2° C—preferably 1.5° C—compared to pre-industrial levels.” These commitments were renewed at the Glasgow COP26 held at the end of 2021.

    As a result of these initiatives, all industrial sectors are under pressure to reduce their GHG emissions and eventually bring these to net zero levels—the “towards zero” target.

    The pharmaceutical industry is no exception

    According to a recent publication,6 the pharmaceutical industry accounts for yearly GHG emissions of around 55 million tons, corresponding to approximatively 0.1% and 2% respectively of the world total and industrial GHG emissions. To use a more tangible yardstick, this is equivalent to the carbon dioxide emitted by twenty million cars. 

    The magnitude of its emissions makes pharma a greater contributor to global warming compared to other industries. For example, car manufacturing is generally considered and intuitively viewed as a heavy polluter, but surprisingly when compared to pharma, its GHG footprint is actually lower—estimated to produce around 80% of the emissions generated by pharma.

    Not surprisingly a number of pharmaceutical companies are actively jockeying for position to reduce their GHG emissions. Several players including AbbVie, Bayer, Biogen, Daichi Sankyo, Eisai, Gilead, J&J, Merck & Co., Merck KGaA, Novo-Nordisk, Sanofi, Takeda and Teva have set near term reduction and/or net zero GHG targets.

    Among these Big Pharma players, AstraZeneca appears to stand out in terms of its commitment to sustainability—the word appeared 188 times in their 2021 annual report. AstraZeneca announced in January 2020 its “Ambition Zero Carbon” strategy involving investments of $1 billion. The objective is to achieve by 2025 zero-carbon emissions from its global operations and ensure that by 2030 its entire supply chain becomes carbon negative. The company has committed to have these initiatives checked through the Net-Zero standards set by the Science Based Target initiative (SBTi).

    AstraZeneca’s high-profile initiatives to move towards zero emissions and more broadly its emphasis on sustainability are probably at least partly prompted by the commitments taken by the UK NHS (National Health Service)—most likely by far its single most important direct customer.

    The NHS is the first health service pledging to reach zero net carbon emissions. To this end, it has launched in 2022 the sustainable supplier framework requesting all its new suppliers to publish by 2024 a reduction plan for their GHG direct emissions—by 2030 only those able to demonstrate progress in line with these preset carbon emission reduction plans will qualify for NHS contracts.

    The elaboration of any GHG emission reduction strategy invariably starts by the systematic analysis of the various emission sources and of their impact. This provides the foundation to identify potential abatement options and ultimately formulate tangible practical implementation action plans. To facilitate the analysis, the various sources of emissions are subdivided in three distinct categories—referred to as “Scope”—based on their origins, position on the activity chain/product life cycle and degree of control played by the entity covered in the analysis. 

    As illustrated in Figure 1, Scope 1 emissions—also defined as “direct” emissions—relate to the entity’s own operations and assets. These cover, for example, the GHG emissions resulting from the combustion of fossil fuels for raising steam in the company’s boilers or for heating/cooling buildings. Scope 2 comprises indirect emissions associated with the various forms of secondary energy purchased from third parties and used in the entity’s own premises—examples include electricity purchased from the grid or steam supplied across the fence by other companies.


    Figure 1. The three GHG emission "Scopes" (Source: adapted from literature)

    All other indirect emissions related to upstream and downstream activities are referred to as Scope 3. Examples of upstream Scope 3 emissions include those associated with the production and transport to the factory gates of purchased goods—be these consumables or machinery—services provided by third parties or business travel. Downstream Scope 3 emissions cover those resulting from the distribution of the company products, their use by customers and their end-of-life disposal.

    According to a recent article6  more than 70% of the GHG emissions of the pharmaceutical industry are Scope 3—Scope 1 and 2 account almost equally for the remaining 30%.

    These estimates are supported by other calculations indicating that the operations directly performed by pharmaceutical companies including production, R&D and administration are responsible for just 20% of total emissions compared with the 32% deriving from the distribution, use and disposal by customers of pharmaceutical products—a set of activities referred to as “post factory/company gate”—the remaining 48% are associated with raw materials and other inputs used.

    While the accuracy of these estimates can be debated—it clearly appears that an “average” pharmaceutical company’s operations account for just a minor share of its total emissions—a situation at least partly reflecting the extensive outsourcing of several activities embraced by the pharmaceutical industry.

    As a consequence, to achieve their GHG emission abatement objectives and eventually reach the zero-carbon target, pharmaceutical companies have no choice but to apply a truly holistic view of their structure and the carbon footprint of the entire supply chain. Such an approach is critical to avoid net zero-sum results where rather than being abated emissions are simply moved and shifted to another entity.

    CDMO partnerships

    An increasing number of pharmaceutical companies are therefore moving for position to ensure that suppliers are effectively aligned with their own GHG abatement strategies and objectives. Within this framework, the procedures for qualifying and selecting suppliers are being extended to include elements such as the vendor’s current GHG footprint, commitment towards its reduction, strategies envisaged/applied to achieve these reductions and the ability to eventually move towards zero emissions or reach selected targets. These may, for example, include pledging to reduce or even eliminate Scope 2 emissions by fully switching to renewable electricity sources.

    Obviously, this implies the supplier must be able to answer a number of questions about how the organization stands in terms of GHG emissions, metrics applied, steps undertaken to date for reducing these emissions and procedures applied for checking the GHG footprint of inputs sourced from third party vendors. In addition, suppliers must be ready to submit a roadmap indicating the decarbonization path envisaged and an associated implementation action plan that also provides tangible milestones for measuring progress.

    Conceptually, these requirements simply represent a logical extension stressing the E dimension of the due diligence process exerted by customers to ensure that their suppliers effectively stick to sound ESG (Environmental, Social and Governance) practices in order to prevent reputational damages. Most pharmaceutical companies these days are accustomed to being scrutinized because it’s been several years that the policies and procedures applied by their vendors on issues such as compliance against bribery, equal employment opportunities, proper handling of waste and other widely accepted sound ESG principles have been implemented.

    However, for many suppliers to the pharmaceutical industry, including most small- to medium-sized CDMOs, the requests associated with their GHG footprint, path to decarbonization or more broadly sustainability are creating an additional element of complexity. At least initially, these increase the cost of being in the business. Barring large companies like Catalent, Evonik or Thermo-Fisher Scientific, many players are ill prepared and equipped, with few even knowing how to calculate their own Scope 1 and 2 carbon emissions.

    This creates a potential source of major vulnerability as the decarbonization and more broadly the sustainability themes correspond to structural developments having an increasingly important impact on all operations and activities. Sooner or later governmental authorities in most Western countries are likely to require all businesses to publish their carbon footprint and report their environmental performance. Indicators such as carbon emissions and amount of waste generated will most probably be increasingly used by governments for taxation purposes. For example, this can be done by imposing a levy per ton of GHG emitted as reflected in the carbon taxes implemented or being considered in various parts of the world.

    Therefore, there is no choice for companies but to adapt to these new requirements by equipping themselves accordingly and being proactive in exploiting the opportunities that these developments are creating rather than just viewing them as threats and eventually being forced to submit to them anyway.

    This is particularly important for CDMOs focusing on the drug substance part of the supply chain. Pharmaceutical fine chemicals in general, and API synthesis more particularly, are notoriously characterized by having a substantial environmental footprint.

    Various metrics are applied for measuring this footprint. Probably the simplest indicator is Ef (E-factor), which measures the amount of waste obtained per unit of final product. In its most basic form this is calculated according to the formula Ef = (A – B) / B) where (A) is the total mass of all input materials used in the synthesis and (B) is the resulting end product mass.  As reported in7 and illustrated in Figure 2. The E-factor in API synthesis is generally estimated between 25 and more than 100.


    Figure 2. E Factor in API synthesis dwarf those observed in the petrochemical industry (Source: adapted from literature)

    In reality this factor is probably even higher as it is often calculated assuming that 90% of solvents used are recovered and recycled while in practice this is rarely the case.

    Irrespective of this, the E-factor observed in API synthesis dwarfs those observed for other types of chemicals. Obviously, this bodes poorly for the overall environmental burden of API synthesis activities in general and more particularly for their carbon footprint. As a first approximation carbon emissions are directly linked to the amount of inputs used—these having to be produced often starting from non-renewable fossil feedstock—and the volumes of waste generated that have to be disposed, eventually resulting in the release in the atmosphere of their carbon content as GHG.

    The high E-factor of API synthesis derives from a number of factors. These include the complexity intrinsic to most of these molecules, the number of processing steps involved in their synthesis and relatively inefficient synthesis processes applied. The latter are at least partly caused by tight timelines preventing the fine tuning and optimization of synthesis processes.

    The ample profit margins and limited impact of cost-of-goods-sold characterizing the pharmaceutical industry also play a role. Combined with regulatory hurdles associated with changing processes for registered products—the limited incentives to optimize costs have often discouraged introducing new and more efficient processes. This is a far cry from what is observed in the petrochemical or base chemical industry where every fraction of percent yield improvement and elimination of wastage has been systematically pursued for many years as epitomized by the Dow Chemical Company in its WRAP motto—Waste Reduction Always Pays—coined in the late 90s.

    Conclusion


    Rather than being cynically viewed as “greenwashing” and a fad, the increasing commitment of pharmaceutical companies to decarbonization, or more generally sustainability, has to be considered by the API CDMO sector as an opportunity to reassess how it operates and ensure alignment with the customer’s objectives and grab associated benefits.

    This requires careful alignment of strategy with business processes, resources and organization. Sustainability and decarbonization considerations must be built in the CDMO strategy. All business processes applied have to be effectively in line with the strategy while adequate resources—whether relating to soft or hardware—have to be on hand for performing these processes and organized accordingly.

    In such a thrust the CDMO owners and senior management must take the lead in demonstrating their genuine commitment to sustainability by setting clear objectives at all levels within the organization and establishing transparent monitoring systems for measuring progress towards these while ensuring adequate alignment of incentives.

    Within this frame, one of the most critical steps is to appoint a person with the required experience, credibility and authority—entrusting he or she with the responsibility to systematically assess the entire company carbon footprint taking into account all three emission scopes (see Figure 1).

    Based on the inventory of the various emission sources and their respective impact—emission reduction options can be identified and analyzed in terms of cost benefits setting the ground for formulating a suitable emission reduction plan.

    This may include steps such as electing to rely only on renewable/green electricity, converting boilers from natural gas to bio-mass, investing in co-generation capacity, increasing shares of solvent recycled, electing to purchase bio-based raw inputs rather than their petrochemical derived counterparts, giving the preference to suppliers located near-by and showing an equal commitment to decarbonization.

    Obviously, the designated person can only succeed if he or she is able to trigger action at the various levels of the organization and make things happen—all company functions have a role to play in the path towards decarbonization and sustainability.

    For example, procurement can identify input sources that have a lower carbon footprint. Marketing and sales can engage in a dialogue with customers while negotiating contractual terms that reflect in prices possible surcharges associated with the use of greener inputs or delivery terms that avoid air freight. Lastly, R&D together with quality assurance can identify opportunities to make processes more efficient while avoiding introducing changes that would create regulatory hurdles. 


    References
    1. Sustainability – Shiji Liu – Bioprocess Engineering (2nd Edition) 2017
    2. Sustainable development – Lees’ Loss prevention in the process industry (4th Edition) 2012
    3. Report of the World Commission on Environment & Development – United Nations 1987
    4. John Elkington – Harvard Business Review June 25, 2018
    5. Sustainability goes mainstream – Blackrock November 2021
    6. Marc Daigneault and David Quinn – A red pill for green medicines – Chemistry World 26 November 2021
    7. Frank Roschangar & al. – Overcoming barriers to green chemistry – Green Chemistry – 24 October 2014


    Dr. Michele Jermini is the Managing Director of Alfa Chemicals (Suisse) SA. He can be reached at mjermini@alfachemicalsint.com

    Dr. Enrico Polastro is a Vice-President of Arthur D. Little. He can be reached at polastro.enrico@adlittle.com

    Related Content

      Loading, Please Wait..
      Breaking News
      • Takeda to Expand U.S. Footprint
      • Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
      • WuXi STA Opens High-Potency API Plant
      • Catalent Expands Primary Packaging Capabilities at its Shiga, Japan Facility
      • Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Pharmavite Expands in Ohio with $200 Million Investment
      Nestlé Health Science Expands in New Zealand with Deal to Buy The Better Health Company
      Younger Consumers Drive Growing Demand for Ingestible Beauty and Skin Care Products
      Coatings World

      Latest Breaking News From Coatings World

      Clariant’s Launches Dispersogen Flex 100
      Lincoln Tech Enters Partnership with AkzoNobel
      AkzoNobel Launches International Interzone 945GF
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      ENDRA Life Sciences Issued 27th Patent
      AI-Enabled SKOUT Device Improves Colorectal Cancer Screening
      Simon Johnson Appointed as Senior Business Development VP at MedAcuity
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Takeda to Expand U.S. Footprint
      Croda Pharma's Lipid Systems Capability to Support mRNA Vaccines
      WuXi STA Opens High-Potency API Plant
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Latest Updates About Cosmoprof North America
      Meet the Clean Beauty Brand for Dogs
      Paco Rabanne Introduces Elle Fanning as Ambassador for New ‘Fame’ Fragrance
      Happi

      Latest Breaking News From Happi

      Two-Part Skincare Product Patented by Estée Lauder Companies
      American Cleaning Institute Pens Letter to Congress Encouraging Examination of Recyclability Improvements
      The Expert Panel for Fragrance Safety Celebrates 55 Years
      Ink World

      Latest Breaking News From Ink World

      INX Launches INXFlex Contour for Shrink Sleeve Market
      Xerox Announces Unexpected Passing of Vice Chairman and CEO John Visentin
      MNYPIA Golf Outing Set to Tee Off on Aug. 17
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Meyers purchased by third generation of Dillon family
      Epson now shipping ColorWorks C4000 inkjet label printer
      Nobelus launches new films for prime labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      What You’re Reading on Nonwovens-Industry.com
      Daio, Livedo Partner to Recycle Diapers
      Suominen Launches Hydraspun Reserve
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      3D Systems and EMS-GRILTECH Enter Strategic Partnership
      AIP Researchers Develop Microfluidic-Based Soft Robotic Prosthetic
      David Sharp Named Global Marketing VP at Catalyst OrthoScience
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Impinj Launches E910 RFID Reader Chip for Next Generation Enterprise IoT
      onsemi Receives Recognition for Sustainability for Third Straight Year
      Xerox Announces the Unexpected Passing of Vice Chairman and CEO John Visentin

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login